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Abstract 
Background: Asthma in the elderly is poorly understood as very few studies have included these patients. DNA 
methylation can affect the expression of asthma susceptibility genes. Methyl groups can be produced through a 
choline dependent pathway. Asthmatics have decreased serum choline. We studied the effect of choline supplemen-
tation in elderly asthmatics and associations between different parameters at baseline.
Methods: This is a double-blind, placebo-controlled, cross-over study. Thirty asthmatics 65 years old and older were 
evaluated at baseline and 3, 6, 9, and 12 weeks later. They randomly received choline bitartrate 310 mg and placebo 
capsules twice daily for 6 weeks.
Results: Ninety percent of the study subjects were atopic and 97 % of them were using inhaled corticosteroids. Cho-
line supplementation did not affect ACT (asthma control test), spirometric values, eosinophil counts or total serum IgE 
vs. placebo (p > 0.86 for all comparisons). In subjects with lower ACT (≤20), lower FEV1 % (<60 %), or higher eosino-
phil counts (≥0.6), there was similarly no difference between choline and placebo (p > 0.63). We found no significant 
association between eosinophil counts and IgE and the other parameters at baseline including in subjects with lower 
ACT or on higher inhaled steroid doses (p > 0.09). Asthmatic women had lower baseline ACT scores compared to 
men (p = 0.02).
Conclusions: In this study of elderly asthmatics, choline supplementation for 6 weeks did not affect ACT scores, 
spirometric values, peripheral blood eosinophils, or total serum IgE. These results will require confirmation in larger 
and longer studies.
Trial registration ClinicalTrials.gov NCT02371993
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Findings
Background
The U.S. population older than 65 years of age is grow-
ing rapidly and will likely increase to about 25  % of the 
total population by the year 2050 [1]. Among individuals 
65 years old and older, about 7 % have asthma [1]. How-
ever, there is little information about asthma in these 
patients as most asthma studies have ignored this group. 
Older asthmatics have higher morbidity and mortality 
and are more likely to be underdiagnosed, undertreated, 
and hospitalized compared to their younger counterparts 
[1].
In elderly patients with asthma, we have previously 
studied the role of exhaled nitric oxide measurements 
and vitamin D [2, 3]. Indeed, there is growing interest in 
the possible role of dietary supplements (e.g., vitamins 
and methyl donors) in asthma [4, 5]. However, most of 
the studies of supplements in asthma have yielded con-
flicting or negative results [4, 5]. DNA methylation is a 
mechanism regulating gene-environment interactions 
in asthma, and its changes can affect asthma by increas-
ing or decreasing the expression of asthma susceptibil-
ity genes [4, 5]. In humans, dietary methyl groups can 
be produced through folate and choline dependent 
pathways.
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Choline is a water soluble essential nutrient important 
in neurotransmission, lipid signalling and membrane 
structure besides being a methyl donor [6]. It forms 
methionine through the methylation of homocysteine. 
Choline is contained in foods such as meat, liver, eggs, 
poultry, fish, shellfish and peanuts. Its deficiency has 
been associated with neurological and cardiovascular 
diseases [7]. Mostly without strong scientific evidence, 
choline supplementation is used for liver disease, neu-
rological diseases including depression, bodybuilding, in 
pregnant women to prevent neural tube defects and as a 
supplement in infant formula.
In mice, choline has been shown to decrease airway 
allergic inflammation and reduce bronchoalveolar lav-
age eosinophils [8]. Individuals with asthma were found 
to have decreased serum choline [9]. An open label 
study of Indian asthmatic adults showed a decrease of 
bronchial hyperreactivity and use of asthma drugs after 
choline supplementation [10]. In the same study, there 
was a reduction of cytokine levels (IL-4 and TNFα) and 
cysteinyl leukotrienes in the supernatants of the patients’ 
blood mononuclear cells stimulated with phytohemoag-
glutinin [10]. In a recent, comprehensive review of vita-
mins and methyl donors in asthma, it was suggested 
that the current evidence strongly justifies clinical trials 
of choline supplementation as an adjuvant treatment in 
asthma [4].
The main purpose of this study was to investigate the 
effect of choline supplementation on asthma symptoms, 
assessed by the asthma control test (ACT), and spiromet-
ric values in elderly asthmatics. This is a double-blind, 
placebo controlled, cross-over study. Secondary objec-
tives of our study included studying whether choline 
supplementation in elderly asthmatics affects peripheral 
blood eosinophil counts and total serum IgE levels. We 
also looked for associations between different parameters 
at baseline.
Methods
This study included five study visits (baseline, and 3, 6, 9, 
and 12 weeks later). Each study subject took one capsule 
of choline bitartrate (310  mg) (Vitamin Shoppe, North 
Bergen, NJ) twice daily (total daily dose = 620 mg daily) 
or one placebo capsule twice daily each for 6 weeks in a 
double-blind, cross-over design. Individuals with his-
tory of gastrointestinal cancers were excluded from this 
study. The bottles containing the unused capsules were 
collected at the end of the two study periods, the remain-
ing capsules counted and their number recorded. Com-
pliance with the study based on capsule count was very 
good (>90 %).
Thirty subjects 65 years old and older with asthma were 
included in the study. Twenty-nine were Caucasian and 
one was African-American. Current smokers or individu-
als with a 10 pack/year or longer history of smoking were 
excluded. Almost all of the study subjects were lifetime 
nonsmokers. The study subjects were recruited among 
interested and eligible patients with asthma followed in 
our practice. Allergic sensitization was verified by allergy 
skin tests for relevant perennial and seasonal allergens.
Spirometric values were obtained according to the 
ATS/ARS guidelines by a KoKo Spirometer (nSpire 
Health, Inc, Longmont, Colorado, USA). The ACT is 
a tool that allows patients to report asthmatic symp-
toms on a scale from 1 (severe) to 5 (no symptoms) by 
answering five questions about asthma control. Values 
lower than 20 are considered as indicative of subopti-
mal asthma control. Inhaled steroid doses are expressed 
as fluticasone equivalent. The inhaled steroids used by 
the study subjects were fluticasone (17), budesonide (7), 
mometasone (4), and beclomethasone (1). Long-acting 
bronchodilators were salmeterol (12) and formoterol 
(8). The only leukotriene antagonist used by the study 
subjects was montelukast. Drug treatment remained 
essentially unchanged throughout the study period. One 
subject was on prednisone 5  mg daily throughout the 
study. Peripheral blood eosinophils were enumerated and 
total serum IgE measured at the Main Line Health Labo-
ratories. This study was approved by the Main Line Hos-
pitals Institutional Review Board (F/N-R15-3427B).
The primary endpoint of this study was to evaluate the 
effect of choline supplementation on the ACT scores. The 
goal was set to see a 10 % improvement (effect size) of the 
ACT score following treatment with choline vs. placebo. 
In our recent study of asthma in the elderly (2), the mean 
ACT score was 22.2 and the standard deviation was 2.8 % 
(n = 30). The calculated standardized effect size is 10 % of 
22.2 (2.2)/2.8 = 0.8. Therefore, β = 0.2 (1/0.8). For an α of 
0.05 (two tailed t test) the number necessary to see a 10 % 
change is 25. Data were expressed as the mean ± stand-
ard deviation and analyzed by the two tailed t test and 
the correlation coefficient as indicated with significance 
accepted at <0.05.
Results
Table  1 summarizes the baseline characteristics of the 
study subjects. Most subjects were atopic (90  %), on 
inhaled corticosteroids (97  %), and had well controlled 
asthma. As shown in Table  2, choline supplementation 
for 3 or 6 weeks did not affect ACT or spirometric values 
when compared to placebo.
Similarly, peripheral blood eosinophil counts and total 
serum IgE were unaffected by choline supplementation 
vs. placebo (Table 3). In subjects with lower ACT (≤20, 
16.7 ± 3.3, n = 6), lower FEV1 % (<60 %, 46.4 ± 9.2 %, 
n = 6), or higher eosinophil counts (≥0.6, 0.88 ± 035 K/
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µL, n = 6) there was also no difference between choline 
and placebo (Table 4). In subjects with lower serum IgE 
(≤151 IU/ml, 68.8 ± 46 IU/ml, n = 18), there was a trend 
for a decrease of the IgE by choline supplementation vs. 
placebo (56.1 ± 36.9 vs. 69. ± 55.4 IU/ml, respectively), 
but this did not reach statistical significance (p = 0.078).
We found no significant association between eosino-
phil counts and IgE (Table  5). Similarly, there was no 
association between eosinophils or IgE and ACT, age, 
body mass index (BMI), steroid dose, or duration of 
asthma (Table  5). In subjects with lower ACT scores 
(16.7 ± 3.3, n = 6), eosinophils and IgE were similar to 
their counterparts with controlled symptoms (p > 0.22). 
Eosinophils were similar in subjects treated with higher 
inhaled steroid dose (≥400 mcg/day, 583 ± 226, n = 13) 
and subjects on lower doses (p  =  0.82). Women had 
lower baseline ACT scores compared to men (21.1 ± 3.7 
vs. 23.6 ± 1.9, respectively, p = 0.02).
Table 1 Subjects’ characteristics at baseline
n = 30
Sex (F/M) 18/12
Age (years, range) 73.7 ± 5.9 (66–84)
BMI 25.6 ± 4.7
Atopy 27/30
Duration of asthma (years) 34.8 ± 21.2
Rhinitis 23/30
Gastroesophageal reflux disease 9/30





Anticholinergic agents (tiotropium) 3/30
Theophylline 1/30
ACT score 22.1 ± 3.3
FEV1 % 75 ± 20.4
FEV1/FVC 0.73 ± 0.1
FEF25-75 % 71 ± 38.2
Peripheral blood eosinophils 0.38 ± 0.31 K/µL
Total serum IgE 198 ± 210 IU/ml
Table 2 Effect of  choline supplementation on  ACT scores 
and spirometric values
n = 30
p > 0.86 for all comparisons
Baseline 3 weeks 6 weeks
ACT (Choline) 22.1 ± 3.3 22.9 ± 2.8 23.4 ± 2
ACT (Placebo) 23.7 ± 1.9 23.2 ± 2.5
FEV1 % (Choline) 75 ± 20.4 75.3 ± 19.3
FEV1 % (Placebo) 76 ± 20
FEV1/FVC (Choline) 0.73 ± 0.1 0.73 ± 0.1
FEV1/FVC (Placebo) 0.73 ± 0.1
FEF25-75 % (Choline) 71 ± 38.2 70 ± 34.2
FEF25-75 % (Placebo) 71.5 ± 34
Table 3 Effect of  choline supplementation on  peripheral 
blood eosinophils counts (K/μL) and  total serum IgE (IU/
ml)
n = 30
p > 0.84 for all comparisons
Baseline 6 weeks
Eosinophils (Choline) 0.38 ± 0.31 0.34 ± 0.27
Eosinophils (Placebo) 0.33 ± 0.27
IgE (Choline) 198 ± 210 206 ± 262
IgE (Placebo) 220 ± 285
Table 4 Effect of  choline supplementation in  different 
patient subgroups
n = 6
p > 0.63 for all comparisons
Baseline 6 weeks
ACT ≤ 20 (Choline) 16.7 ± 3.3 21.5 ± 3
ACT ≤ 20 (Placebo) 22.3 ± 2.9
FEV1 % < 60 % (Choline) 46.4 ± 9.2 47 ± 10.3 
FEV1 % < 60 % (Placebo) 46.6 ± 6.8 
Eosinophils ≥ 0.6 K/µL (Choline) 0.88 ± 0.35 0.62 ± 0.4
Eosinophils ≥ 0.6 K/µL (Placebo) 0.62 ± 0.5
Table 5 Associations between  different parameters 
at baseline
n = 30
p > 0.09 for all associations
R
Eosinophils vs. IgE 0.180
Eosinophils vs. age 0.069
Eosinophils vs. ACT 0.071
Eosinophils vs. BMI −0.003
Eosinophils vs. inhaled steroid dose −0.034
Eosinophils vs. duration of asthma −0.308
IgE vs. age −0.243
IgE vs. ACT 0.019
IgE vs. BMI 0.154
IgE vs.inhaled steroid dose −0.145
IgE vs. duration of asthma 0.008
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None of the subjects reported adverse effects during 
the course of the study.
Discussion
In this study, we investigated the effect of choline supple-
mentation in elderly subjects with asthma. This group of 
patients has been mostly ignored in previous studies of 
this condition.
Choline supplementation for 6  weeks did not affect 
asthma symptoms or spirometric values, including in the 
subgroups of subjects with lower ACT scores and FEV1 
values. Similarly, peripheral blood eosinophil counts and 
total serum IgE were unaffected by choline supplementa-
tion. These results suggest that supplementing this methyl 
donor has no effect on clinical and biologic parameters in 
elderly asthmatics. We cannot rule out that longer stud-
ies using higher doses of choline may have a different 
outcome. However, an open label study of Indian adults 
with asthma similarly showed that the same parameters 
were unaffected by choline chloride supplementation 
for 6 months [10]. Such study employed higher doses of 
choline than utilized in our study. In contrast, the same 
senior author of that study had previously reported that 
tricholine citrate supplementation for 16 weeks lead to an 
improvement in asthma symptom scores in small cohorts 
(10–12 subjects) of adolescent and young adults [11, 12]. 
One of these two studies was single blinded and the other 
was open label. It is unclear whether different formula-
tions of choline may affect clinical response.
While blood eosinophil counts are similar in younger 
and older asthmatics, total serum IgE is significantly 
lower in elderly than in nonelderly asthmatic subjects 
[13]. In a study of adults with asthma, antigen specific 
serum IgE was associated with blood eosinophil counts 
[14]. We found no association between eosinophils and 
total serum IgE, or other parameters at baseline.
The results indicating that asthmatic women have 
lower symptom scores than men are in agreement with a 
recent study showing an association between female sex 
and poorer asthma symptom scores [15].
Although choline supplementation is considered fairly 
safe, and none of our study subjects experienced side 
effects during the study, one study found that a high die-
tary intake of choline was associated with an increased 
risk of colon adenomas in women [16].
Limitations of this study include the relatively small 
number of subjects, almost exclusively Caucasians and 
atopic with well controlled asthma. It is possible that 
including more subjects with uncontrolled symptoms 
and/or non atopic asthma could yield different results. In 
addition, it is also possible that choline supplementation 
may affect biologic markers that were not assessed in our 
study (e.g., cytokines, periostin).
Conclusions
In summary, in this pilot study of elderly asthmatics, 
choline supplementation for 6 weeks did not affect ACT 
scores, spirometric values, blood eosinophils or serum 
IgE. These results will require confirmation in subjects 
with uncontrolled symptoms, in other ethnic groups, and 
following a longer treatment period with higher dose of 
choline.
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